Research Papers:
Human mesenchymal stem cells preferentially migrate toward highly oncogenic human hepatocellular carcinoma cells with activated EpCAM signaling
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1678 views | HTML 2745 views | ?
Abstract
Berwini Endaya1,2,*, Shou P. Guan1,*, Jennifer P. Newman1, Hung Huynh1, Kian C. Sia1, Siao T. Chong1, Catherine Y.L. Kok1, Alexander Y.F. Chung3, Bin B. Liu4, Kam M. Hui6,7,8 and Paula Y.P. Lam1,5,8
1Division of Cellular and Molecular Research, National Cancer Centre, Singapore City, Singapore
2Griffith Health Institute, Griffith University, Southport, Australia
3Department of General Surgery, Singapore General Hospital, Singapore City, Singapore
4Liver Cancer Institute of Fudan University, Shanghai, China
5Department of Physiology, National University of Singapore, Singapore City, Singapore
6Department of Biochemistry, National University of Singapore, Singapore City, Singapore
7Institute of Molecular and Cell Biology, A*STAR, Singapore City, Singapore
8Cancer and Stem Cells Biology Program, Duke-NUS Graduate Medical School, Singapore City, Singapore
*These authors are considered as co-first authors
Correspondence to:
Paula Y.P. Lam, email: [email protected]
Keywords: human bone marrow-derived MSC, tumor tropism, EpCAM signaling, human hepatocellular carcinoma
Received: September 16, 2016 Accepted: February 27, 2017 Published: May 05, 2017
ABSTRACT
The epithelial cell adhesion molecule (EpCAM) is a type I transmembrane glycoprotein that is regarded as one of the markers for tumor initiating cells (TIC) in human hepatocellular carcinoma (HCC). Much work has been directed towards targeting these TICs as a mean of placing these master regulators of cell proliferation and drug resistance under control. Human bone marrow-derived mesenchymal stem cells are known to exhibit an innate property of tumor tropism. However, the possible relationship between MSC and TIC is not well understood. In this study, we show that MSC migration to HCC can be effectively inhibited by TACE and γ-secretase inhibitors that stop the activation of EpCAM signaling event. Silencing of EpCAM expression through siRNA and antibody approaches also resulted in impaired MSC migration. By contrast, increase levels of EpICD proteins in HCC cells and HCC mouse xenografts resulted in enhanced MSC migration. Taken together, these findings show that MSC is drawn to the more oncogenic population of HCC, and could potentially serve as a cell-based carrier of therapeutic genes to target EpICD-enriched hepatic tumor cells.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17633